- 1 **Title:** COVID-19 Testing and Vaccination among US Older Adults with Vision Impairment: The
- 2 National Health and Aging Trends Study 2021
- 3
- 4 Authors: Louay Almidani, MD, MSc¹, Bonnielin K. Swenor, PhD, MPH^{2,3}, Joshua R. Ehrlich, MD,
- 5 MPH^{4,5}, Varshini Varadaraj, MD, MPH^{2,3}
- 6

7 Affiliations

- 8 ¹ Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
- 9² Johns Hopkins Disability Health Research Center, Johns Hopkins University, Baltimore,
- 10 Maryland
- ³ Johns Hopkins University School of Nursing, Baltimore, Maryland
- ⁴ Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor
- 13 ⁵ Institute for Social Research, University of Michigan, Ann Arbor
- 14

15 Abstract

- Purpose: To examine the associations between vision impairment (VI) and COVID-19 testing
 and vaccination services in older US adults.
- 18

Methods: This cross-sectional study assessed data from adults ≥65 years who participated in the National Health and Aging Trends Study (year 2021), a nationally representative sample of Medicare beneficiaries. Exposure: Distance VI (<20/40), near VI (<20/40), contrast sensitivity impairment (CSI) (<1.55 logCS), and any VI (distance, near, or CSI). Outcomes: Self-reported COVID-19 testing and vaccination.

24

25 **Results:** Of 2,822 older adults, the majority were female (weighted; 55%) and White (82%), and 26 32% had any VI. In fully-adjusted regression analyses, older adults with any VI had similar 27 COVID-19 vaccination rates to adults without any VI (OR:0.77, 95% CI:0.54–1.09), but had lower 28 odds of COVID-19 testing (OR:0.82, 95% CI:0.68–0.97). Older adults with distance (OR:0.47, 95% 29 CI:0.22-0.99) and near (OR:0.68, 95% CI:0.47-0.99) VI were less likely to be vaccinated for 30 COVID-19, while those with CSI were less likely to test for COVID-19 (OR:0.76, 95% CI:0.61-31 0.95), as compared to peers without respective impairments. The remaining associations were 32 not significant (p>.05).

33

34 **Conclusions and Relevance:** These findings highlight inequities in the COVID-19 pandemic 35 response for people with vision disability and emphasize the need for equitable prioritization of 36 accessibility of healthcare services for all Americans.

37 **1. Introduction**

COVID-19, stemming from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a significant contributor to morbidity and mortality, with the elderly population emerging as the most susceptible cohort.¹ Further, older age is also often associated with an increased prevalence of vision impairment (VI).² As a result, adults with VI may be at a higher risk of experiencing severe COVID-19 outcomes, underscoring the importance of preventive healthcare services, including vaccinations.

44

The development of the COVID-19 vaccine has caused a major shift during the pandemic, resulting in millions of lives saved globally. Watson et al (2022) estimated that vaccinations prevented over 14 million deaths from COVID-19 across 185 countries and territories.³ Nonetheless, the impact of vaccinations has been hindered by the inadequate vaccine accessibility in certain communities.³

50

The COVID-19 pandemic has had a disproportionate impact on people with disabilities, including those with VI.⁴ It has exacerbated existing barriers in accessing essential preventive healthcare services, such as vaccination and testing.⁵ Studies have shown that adults with VI are less likely to use preventive services,⁶ including lower vaccine initiation rates,⁷ and experience worse health outcomes than adults without VI.⁸ Additionally, individuals with VI may face challenges in navigating healthcare systems and accessing public health information, which could increase their risk of COVID-19 or other illnesses.⁹

58

59 Despite these associations, previous studies lacked generalizability or only assessed one aspect 60 of vision. Vision is a complex process, and while distance visual acuity (the ability to see objects at a distance) is most frequently used in research studies as a measure of visual function.¹⁰ it 61 only represents one component of visual function.¹¹ Recent findings suggest that other aspects 62 of vision, such as near visual acuity (the ability to see objects located close to the eyes, which is 63 64 important for tasks like reading) and contrast sensitivity (the ability to perceive differences in shades and distinguish objects from their background), can also impact daily functioning.¹²⁻¹⁴ 65 66 Accordingly, we utilized data from the National Health and Aging Trends Study (NHATS), a US 67 68 population-based, nationally representative sample of Medicare beneficiaries, to assess the 69 potential associations of three measures of vision — distance visual acuity (VA), near VA, and 70 contrast sensitivity (CS) — with COVID-19 vaccination and testing in a national sample of older adults. as they are at risk of VI and worse COVID-19 outcomes.⁴ 71

72

73 **2. Materials and Methods**

74 2.1 Study design and participants

This cross-sectional study presents data from the NHATS Round 11 (2021), a nationally representative sample of Medicare beneficiaries aged ≥65 years in the United States.¹⁵ In-home interviews and performance-based tests, including vision testing, were conducted annually from approximately June to November.¹⁶ Further details regarding survey sampling design have been previously described.^{15,16} Written informed consent was obtained from all participants or their proxies. This secondary analysis of publicly available data was acknowledged as exempt

research by the institutional review board of the Johns Hopkins School of Medicine. The study
 adheres to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
 reporting guidelines for cross-sectional studies.

84

85 2.2 Vision Measures

In 2021, the NHATS introduced three objective vision tests (distance and near VA, and CS) that measured presenting binocular vision while wearing habitual correction (glasses or contacts). Tests were conducted via Ridgevue Vision tablet-based tests (ridgevue.com), which show good agreement with corresponding gold standard tests (ETDRS distance acuity, MNRead near acuity, and Pelli-Robson contrast sensitivity), and enable standardized monitoring to occur in a variety of settings, including at home or in rehabilitation facilities.^{17,18}

92

93 For distance VA testing, participants sat five feet away from the tablet and were instructed to 94 read five letters per screen with each subsequent screen displaying reduced letter size. For near 95 VA testing, participants held the tablet at their usual reading distance and were instructed to 96 read five letters per screen with each subsequent screen displaying smaller letters. For CS 97 testing, participants were instructed to read two letters per screen, with the tone becoming lighter with each subsequent screen. Further details on how the tests were conducted have 98 been described previously.^{17,19} Distance and near VA were calculated as the logarithm of the 99 100 minimum angle of resolution (logMAR), with near VA accounting for reading distance. CS was 101 measured in logCS units. We assessed vision on a continuous scale; distance and near VA (per 102 0.1 logMAR), and CS (per 0.1 logCS), and on a categorical scale; distance VI (<20/40), near VI

103 (<20/40) – based on the US American Academy of Ophthalmology definitions, 20 – and CS

104 impairment (CSI) (<1.55), as previously defined.²¹ Any objective VI was defined as having VI in

105 either distance, near, or CS, and was taken as the primary exposure.

106

107 2.3 Outcomes

We examined two sets of outcomes: COVID-19 vaccination and COVID-19 testing. Participants were considered to have been COVID-19 vaccinated or tested if they answered "yes" to any of the following questions respectively: (1) Have you been vaccinated for COVID-19? (2) Have you ever been tested for COVID-19? Outcomes were based on self-reports and were recorded in the NHATS dataset as binary variables (yes/no).

113

114 2.4 Covariates

115 Demographic characteristic covariates included age (categorized into five age intervals: 70-74, 116 75-79, 80-84, 85-89, and ≥90; continuous age is not provided in the publicly available NHATS 117 data), gender (male, female), race (Non-Hispanic White, Non-Hispanic Black, Hispanic, and 118 other), education (\leq high school, some college, and \geq college graduate), living arrangements 119 (alone or not alone), and number of comorbidities (0-1, 2, 3, and \geq 4). Comorbidities include 120 self-reported diagnoses of diabetes, hypertension, myocardial infarction, arthritis 121 (osteoarthritis or rheumatoid arthritis), osteoporosis, stroke, lung disease (such as emphysema, 122 asthma, or chronic bronchitis), cancer, and hip fracture. Covariates were included based on 123 clinical relevance and/or previous demonstration of impact on VI and preventive healthcare 124 use.

125

126 2.5 Statistical Analysis

In NHATS Round 11, a total of 3,817 participants were sampled, and interview data were obtained by direct contact with either the participant or a proxy respondent. Figure 1 describes the analytic population. Descriptive statistics were used to characterize the participants by any VI status. Comparisons were performed using Pearson's chi-squared test for categorical variables and Wilcoxon rank-sum test for continuous variables.

132

133 Multivariable logistic regression models were used to investigate the association between 134 various vision measures and COVID-19 vaccination and testing. While our primary exposure was 135 any VI, we constructed separate regression models for each vision variable, including distance 136 VI, near VI, and CSI. We also assessed vision on a continuous scale; distance and near VA (per 137 0.1 logMAR), and CS (per 0.1 logCS). All analyses accounted for the NHATS complex survey 138 design and models were adjusted for age, sex, race/ethnicity, education, living arrangement, 139 and comorbidities. "Don't know" and "Refuse" responses were treated as missing values and 140 excluded from the regressions. Statistical significance was defined at p<.05 and 2-sides values 141 are presented. All analyses were performed using Stata/SE 16.1 (StatCorp LLC, College Station, 142 TX, USA) software.

143

Among a sample of 2,822 community-dwelling older adults representing 26,182,090 older adults nationally, the majority was female (55%) and White (82%), and 32% had any VI (**Table**

¹⁴⁴ **3.** Results

147 **1**). Of the total sample, 91% adults were vaccinated for COVID-19, and 53% had ever tested for 148 COVID-19. The prevalence of COVID-19 vaccination did not differ by any VI status, but the 149 prevalence of COVID-19 testing was 11% lower among adults with any VI than adults without 150 VI. Further, COVID-19 vaccination rates were 5% lower in adults with near VI (vs. no near VI), 151 while COVID-19 testing rates were 15% lower in adults with CSI (vs. no CSI). There were no 152 significant differences in the COVID-19 vaccination and testing rates for the other vision 153 measures (Figure 2).

154

In multivariable logistic regression analysis, older adults with any VI had similar COVID-19 vaccination rates compared to adults without (OR: 0.77, 95% CI: 0.54–1.09), but had lower odds of testing for COVID-19 (OR: 0.82, 95% CI: 0.68–0.97) (**Table 2**). When examining individual objective vision measures categorically, older adults with distance (OR: 0.47, 95% CI: 0.22–0.99) and near (OR: 0.68, 95% CI: 0.47–0.99) VI had lower odds of being vaccinated, and adults with CSI were less likely to test for COVID-19 (OR: 0.76, 95% CI: 0.61–0.95), than their respective peers without impairments. The remaining associations were not significant (p>.05).

162

When examined on a continuous scale, adults with worse distance (OR: 0.48, 95% CI: 0.24– 0.96), and near (OR: 0.32, 95% CI: 0.16–0.65) VA, (per 0.1 logMAR) were less likely to be vaccinated, however, only adults with worse distance VA were less likely to test for COVID-19 (OR: 0.41, 95% CI: 0.26–0.65). Similarly, adults with worse CS (per 0.1 logCS) were less likely to test for COVID-19 (0.50, 95% CI: 0.36–0.71) but did not have differences in vaccination rates as compared to peers without CSI.

169

170

4. Discussion

In a nationally representative sample of US older adults, adults with VI were less likely to get 172 173 vaccinated or tested for COVID-19, depending on the measure of visual function. Interestingly, 174 for each 0.1 logMAR deterioration in distance or near VA, the likelihood of seeking COVID-19 175 vaccination was reduced to less than half. Similarly, the odds of undergoing COVID-19 testing 176 were equal to or less than half per 0.1 logMAR in distance VA and 0.1 logCS in CS compared to 177 their counterparts without respective impairments. Conversely, near VA (per 0.1 logMAR) trended towards lower odds of undergoing COVID-19 testing, while CS (per 0.1 logCS) trended 178 179 towards lower odds of vaccination, though neither reached statistical significance.

180

181 Our findings are consistent with prior studies showing that people with VI are less likely to utilize COVID-19 healthcare services.^{7,22} This may be due to a range of barriers within the 182 183 healthcare system, such as issues with accessibility of information and services, and insurance.^{4,5,23} In particular, adults with VI may experience greater difficulties with accessing 184 185 COVID-19 information on public websites due to poor CS and other webpage accessibility 186 challenges.⁴ Additionally, transportation to drive-through testing sites posed a significant hurdle 187 in accessing testing and vaccination services, which were exacerbated by regulations such as social distancing mandates.^{4,5,23} These findings are concerning, as vaccinations are essential in 188 maintaining health, and preventing severe COVID-19-associated outcomes.²⁴ Future work is 189 190 needed to examine if these disparities in COVID-19 healthcare services translate to worse 191 COVID-19-related health outcomes for older adults with VI.

192

193 It is essential to recognize the challenges faced by the VI community and develop strategies to 194 promote health equity and improve access to essential healthcare services. One such strategy is 195 to move towards universal design principles, which aim to create products, environments, and 196 systems that are accessible to everyone, including people with disabilities.²⁵ By promoting 197 universal design and addressing inaccessibility, we can ensure that individuals with VI have 198 equal access to healthcare services, thereby improving their independence, health, and overall 199 well-being.

200

201 Our study has some limitations. It is unclear what is meant by "been vaccinated for COVID-19?" 202 as NHATS does not specify whether it refers to full primary vaccination or one of two doses. 203 Further, the NHATS does not specify the type of COVID-19 test used (polymerase chain reaction 204 vs. antigen), or testing location (home test vs. or testing center). It is worth noting that some 205 vision measures were associated with lower testing and vaccination, while others were not. 206 This may reflect real-world differences in how various vision measures impact individuals' 207 functioning but could also be influenced by the sample size and statistical power. Irrespective, 208 overall, these findings suggest that VI is associated with reduced utilization of COVID-19 testing 209 and vaccination services among older adults.

210

211 **5.** Conclusion

This study highlights the inequities in the COVID-19 pandemic response for older Americans with vision disability and emphasizes the importance of prioritizing accessibility of healthcare services, especially COVID-19 testing and vaccination services for all people.


- **Acknowledgement/Financial Support**: None relevant to work presented.
- **Conflict of Interest**: All listed authors have no conflicts of interest in any materials discussed in
- this article.
- **Data availability statement:** Data is publicly available at <u>https://nhats.org/researcher</u>

222 <u>References:</u>

224	1.	Banerjee D. The impact of Covid-19 pandemic on elderly mental health. Int J Geriatr
225		Psychiatry. 2020;35(12):1466-1467. doi:10.1002/gps.5320
226	2.	Almidani L, Varadaraj V, Mihailovic A, Ramulu PY. Using Objective Vision Measures to
227		Explore the Association of Vision Impairment With Cognition Among Older Adults in the
228		United States. Am J Ophthalmol. 2023;255:18-29. doi:10.1016/j.ajo.2023.05.020
229	3.	Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the
230		first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis.
231		2022;22(9):1293-1302. doi:10.1016/S1473-3099(22)00320-6
232	4.	Jo G, Habib D, Varadaraj V, et al. COVID-19 vaccine website accessibility dashboard.
233		Disabil Health J. 2022;15(3):101325. doi:10.1016/j.dhjo.2022.101325
234	5.	Epstein S, Campanile J, Cerilli C, Gajwani P, Varadaraj V, Swenor BK. New obstacles
235		and widening gaps: A qualitative study of the effects of the COVID-19 pandemic on U.S.
236		adults with disabilities. Disabil Health J. 2021;14(3):101103.
237		doi:10.1016/j.dhjo.2021.101103
238	6.	Assi L, Varadaraj V, Shakarchi AF, et al. Association of Vision Impairment With
239		Preventive Care Use Among Older Adults in the United States. JAMA Ophthalmol.
240		2020;138(12):1298. doi:10.1001/jamaophthalmol.2020.4524
241	7.	Turner K, Nguyen OT, Alishahi Tabriz A, Islam JY, Hong YR. COVID-19 Vaccination
242		Rates Among US Adults With Vision or Hearing Disabilities. JAMA Ophthalmol.
243		2022;140(9):894. doi:10.1001/jamaophthalmol.2022.3041
244	8.	Varadaraj V, Ehrlich JR, Swenor BK. Vision Impairment Has Implications for Aging and
245		Health Outcomes, Beyond Ophthalmology. JAMA Netw Open. 2022;5(5):e2214610.
246		doi:10.1001/jamanetworkopen.2022.14610
247	9.	Spencer C, Frick K, Gower E, Kempen J, Wolff J. Disparities in Access to Medical Care
248		for Individuals with Vision Impairment. Ophthalmic Epidemiol. 2009;16(5):281-288.
249		doi:10.3109/09286580902999439


250	10.	HAEGERSTROM-PORTNOY G, SCHNECK ME, LOTT LA, BRABYN and JA. The
251		Relation Between Visual Acuity and Other Spatial Vision Measures. Optometry and
252		Vision Science. 2000;77(12):653-662. doi:10.1097/00006324-200012000-00012
253	11.	Varadaraj V, Ehrlich JR, Swenor BK. Vision Impairment Has Implications for Aging and
254		Health Outcomes, Beyond Ophthalmology. JAMA Netw Open. 2022;5(5):e2214610.
255		doi:10.1001/jamanetworkopen.2022.14610
256	12.	Myers VS. Distance and Near Visual Acuity, Contrast Sensitivity, and Visual Fields of
257		10-Year-Old Children. Archives of Ophthalmology. 1999;117(1):94.
258		doi:10.1001/archopht.117.1.94
259	13.	Varadaraj V, Munoz B, Deal JA, et al. Association of Vision Impairment With Cognitive
260		Decline Across Multiple Domains in Older Adults. JAMA Netw Open.
261		2021;4(7):e2117416. doi:10.1001/jamanetworkopen.2021.17416
262	14.	Swenor BK, Simonsick EM, Ferrucci L, Newman AB, Rubin S, Wilson V. Visual
263		Impairment and Incident Mobility Limitations: The Health, Aging and Body Composition
264		Study. J Am Geriatr Soc. 2015;63(1):46-54. doi:10.1111/jgs.13183
265	15.	Vicki A. Freedman, Jennifer A. Schrack, Maureen E. Skehan, and Judith D. Kasper. 2022.
266		National Health and Aging Trends Study User Guide: Rounds 1-11 Final Release.
267		Baltimore: Johns Hopkins University School of Public Health. Available at
268		www.NHATS.org. (https://www.nhats.org/sites/default/files/2022-
269		11/NHATS_User_Guide_R11_Final_Release.pdf).
270	16.	Freedman VA, Kasper JD. Cohort Profile: The National Health and Aging Trends Study
271		(NHATS). Int J Epidemiol. 2019;48(4):1044-1045g. doi:10.1093/ije/dyz109
272	17.	Hu, Mengyao, Joshua R. Ehrlich, Nicholas S. Reed, Vicki A. Freedman. 2022. National
273		Health and Aging Trends Study (NHATS) Vision and Hearing Activities User Guide.
274		Johns Hopkins University School of Public Health. Available at www.NHATS.org.
275		(https://www.nhats.org/sites/default/files/2022-
276		07/NHATS%20Vision%20and%20Hearing%20Activities%20User%20Guide.pdf).
277	18.	Varadaraj V, Assi L, Gajwani P, et al. Evaluation of Tablet-Based Tests of Visual Acuity
278		and Contrast Sensitivity in Older Adults. Ophthalmic Epidemiol. 2021;28(4):293.
279		doi:10.1080/09286586.2020.1846758

- 280 19. Hu M, Freedman VA, Ehrlich JR, Reed NS, Billington C, Kasper JD. Collecting
- 281 Objective Measures of Visual and Auditory Function in a National in-Home Survey of
- 282 Older Adults. J Surv Stat Methodol. 2021;9(2):309-334. doi:10.1093/JSSAM/SMAA044
- 283 20. Low Vision American Academy of Ophthalmology. Accessed April 10, 2023.
- 284 https://www.aao.org/education/low-vision-and-vision-rehab
- 285 21. Mäntyjärvi M, Laitinen T. Normal values for the Pelli-Robson contrast sensitivity test. J
 286 Cataract Refract Surg. 2001;27(2):261-266. doi:10.1016/S0886-3350(00)00562-9
- 287 22. Ryerson AB, Rice CE, Hung MC, et al. Disparities in COVID-19 Vaccination Status,
- 288 Intent, and Perceived Access for Noninstitutionalized Adults, by Disability Status —
- 289 National Immunization Survey Adult COVID Module, United States, May 30–June 26,
- 290 2021. MMWR Morb Mortal Wkly Rep. 2021;70(39):1365-1371.
- 291 doi:10.15585/mmwr.mm7039a2
- 292 23. Shalaby WS, Odayappan A, Venkatesh R, et al. The Impact of COVID-19 on Individuals
- Across the Spectrum of Visual Impairment. *Am J Ophthalmol*. 2021;227:53-65.
 doi:10.1016/j.ajo.2021.03.016
- 295 24. Yuan Y, Thierry JM, Bull-Otterson L, et al. COVID-19 Cases and Hospitalizations
- Among Medicare Beneficiaries With and Without Disabilities United States, January 1,
- 297 2020–November 20, 2021. MMWR Morb Mortal Wkly Rep. 2022;71(24):791-796.
- 298 doi:10.15585/mmwr.mm7124a3
- 299 25. Samuel LJ, Xiao E, Cerilli C, et al. The development of the Supplemental Nutrition
- 300 Assistance Program enrollment accessibility (SNAP-access) score. *Disabil Health J*.
- 301 2022;15(4):101366. doi:10.1016/j.dhjo.2022.101366
- 302
- 303



COVID-19 data (n=2,822)

COVID-19 Vaccination



COVID-19 Testing